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The carboxy-terminal half of the c-src protein fused to the protein A moiety was expressed m bacterta. The protein A/truncated C-SW fusion protein. 
whrch does not have SH2 and SH3 domains, is found in the periplasmtc space allowing for a sample one-step purification and demonstrated hrgh 
efficiency in autophosphorylation and exogeneous substrate phosphorylatton The missense mutation at codon 294 (Be + Thr), which IS located 
in the ATP-binding domain of the C-SK, resulted in dramatic reduction of tyrosine kinase activity of the fuston protem. Using the fusron protem, 
we also revealed that staurosporin. a well-known kinase inhibitor, directly affects autophosphorylatron of the C-terminal half of the C-SK protein. 
Thts truncated C-SK expression system provides a good source of enzyme for diverse experiments and is an ideal model for understanding the 
implication of structural alterations in the catalytic activity of the C-SW kinase by site-directed mutagenesis experiments. 
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1. INTRODUCTION 
Non-receptor protein tyrosine kinases (PTKs) of the 
c-n-c family are important intermediates in signal 
transduction pathways, coupling diverse signals medi- 
ated through tyrosine kinase receptors with a variety of 
downstream mediators. Additionally, activation of 
some of these kinases has been implicated as an impor- 
tant event(s) in the development and/or progression of 
several human tumors including chronic myelogenous 
leukemia, colon cancer, and neuroblastoma [l-7]. Thus, 
identifying the mechanisms by which these kinases in- 
teract with specific substrates, determining the aberrant 
processes that lead to their activation, and developing 
specific inhibitors of the tyrosine kinase activity of this 
class of molecules are active areas of research. Toward 
these goals, considerable effort has been devoted to ex- 
pressing and purifying large quantities of individual ty- 
rosine kinases in bacterial and insect cell systems. How- 
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ever, most bacterially expressed PTKs aggregate in in- 
clusion bodies, and purification results in loss of enzy- 
matic activity. Therefore, bacterially expressed PTKs 
have been used primarily to obtain immunogenic pro- 
teins for the production of antibodies [8.9]. Only a few 
bacterially expressed PTKs have enzymatic activity; 
these include v-src [lo], v-abl [l 1.121, v-fps [13], and 
c-abl [14]. The expression of enzymatically active c-srL 
protein in bacteria has not been described to date. The 
baculovirus system has been used for the successful pu- 
rification of c-lck [15,16]. Although this system shows 
great promise, attempts to purify pp60”-“” have been 
complicated by its toxicity, low specific activity, and low 
levels of expression [17]. 
Recently, alternate approaches have been used to 
study the kinase sequences responsible for enzymatic 
activity and specificity. The SH2 domain of ~~60’~” has 
been expressed, purified and crystallized [18]. These 
fragments are providing important information about 
the role of these domains in binding specific substrates. 
To purify the catalytic domain of the proteins, one 
successful approach has been to fuse the eukaryotic 
protein to a bacterial protein and to its expression in 
bacterial cells. Nilsson et al. [19] developed plasmid 
pRIT5, which contains the gene coding for staphylococ- 
cal protein A and is adapted for gene fusion. This vector 
allows fusion of any gene to the protein A moiety, giving 
rise to fusion proteins that can be purified in a one-step 
procedure using IgG affinity chromatography. Moreo- 
ver, the vector was designed for secretion, giving a 
periplasmic fusion protein in Escherichia coli and an 
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extracellular protein in Gram-positive hosts such as 
Staphylococcus aureus. 
In the present study, we have established the bacterial 
expression of the carboxy-terminal half of the C-SW pro- 
tein using a protein A fusion protein expression system. 
The protein A/truncated C-SW fusion protein has been 
detected to have tyrosine kinase activity, which indi- 
cates that the minimal kinase domain of pp60”-“’ is 
efficient for PTK catalytic activity. Furthermore, by 
using this recombinant protein, we determined that 
staurosporin, a well-known tyrosine kinase inhibitor, 
suppressed activity of this carboxyl-terminal half of c- 
SYC kinase in vitro. 
2. MATERIALS AND METHODS 
2.1. Plasnd construction 
Plasmid pRIT5 (Pharmacia, Piscataway, NJ), containing the gene 
coding for staphylococcal protein A and adapted for gene fusion [19]. 
has been used for constructing the truncated ~~60’~“” expression plas- 
mid. Plasmid pRSVc-srcNP was kindly provided by Dr. J. Brugge [20] 
The carboxy-terminal half of the C-SW cDNA fragment (c-srcNP). 
which has a deletion of amino acids 15 to 225, was prepared by a 
polymerase chain reaction (PCR) using the pRSVc-srcNP plasmid as 
a PCR template PCR was performed according to the method of Saiki 
et al. [21] with modifications. Target sequences were amplified in a 100 
,uI reaction volume containmg 20 ng of plasmid (pRSVc-srcNP) DNA, 
1.25 mM deoxyadenosine triphosphate, 1.25 mM deoxycytidine tri- 
phosphate, 1.25 mM deoxyguanosme triphosphate, 1.25 mM de- 
oxythymidine triphosphate, 10 mM Tris-HCl (pH 8.3). 50 mM KCl, 
1.5 mM MgCl>, 0.01% gelatin. 50 pmol of the each primer (SR-I: 
5’-CTGGAATTCCATTGAAGGCCGCATGGGGAGCAGCAAG- 
AGCAAGC-3’. SR-2: 5’-GGGGATCCAGGCCTATAGGTTCTC- 
TCCA-3’) and 2.5 units of recombinant Taq DNA polymerase (Am@- 
Taq: Perkin Elmer Cetus, Norwalk, CT). Cycling reactions were per- 
formed in a DNA Thermal Cycler (Perkin Elmer Cetus. Norwalk, 
CT). Each cycle consisted of denaturation at 94°C for 90 s. annealing 
at 60°C for 60 s. and extension at 72°C for 90 s. A total of 30 cycles 
were performed. Since additional sequences containing restriction en- 
donuclease recogmtion sites were attached to the 5’ end of the PCR 
extension primers, these sequences were incorporated in the PCR 
product after each subsequent PCR cycle: EcoRI and BanrHl sites in 
SR-1 and SR-2. respectively. The PCR product was purified and 
enzymatically digested with EcoRI and BarnHI. The purified DNA 
fragment was ligated into pRIT5 plasmid DNA, which was digested 
with EcoRI and BantHl by using T4 hgase. Competent bacteria cells. 
DHSa, were transformed with the ligation mixture. The transformed 
bacteria colonies were screened by the colony hybridization method. 
and positive colonies were picked and grown. The DNA sequences of 
the srcNP cDNA inserted into the plasmid were confirmed by the 
dideoxynucleotide chain termination method [22] 
2.2. Expresston of protein Altruncated c-src fusion protein in E. coli 
Bacteria was grown in LB media containing ampicillin (50 pglml) 
overnight and harvested by centrifugation. To determine the prefera- 
ble culture condition for the recombinant protein. two different tem- 
peratures (37°C and 25°C) were used for culturing the bacterial cells. 
Periplasmic proteins were collected by osmotic shock treatment as 
follows Bacterial pellets were resuspended in l/4 volume of sucrose 
solution containing 20% sucrose, 0.3 M Tris-HCI (pH 8) 1 mM 
EDTA, and 0.5 mM MgCl, and incubated for 10 min at room temper- 
ature. The cells were centrifuged and resuspended in l/4 volume of 0.5 
mM ice-cold MgCIZ. After incubation on ice for 10 min. the cells were 
centrifuged at 10,000 x g for IO min at 4°C. The periplasmic proteins 
were harvested from supernatant and utilized for purification, kinase 
assays and immunoblot analysis. 
2.3. Kmase assal 
In vitro phosphorylation assays were performed as previously de- 
scribed [23] with modifications. The periplasmic proteins (250,~g total 
protein) were incubated with IgG-Sepharose 6FF (Pharmacia, Pis- 
cataway. NJ) at 4°C for 1 h. After 3 washes with washing buffer (10 
mM sodium phosphate, pH 7.4, 150 mM NaCl and 0.1% Triton-X), 
the pellet was incubated m 50 ~1 of a kmase buffer contaming 20 mM 
HEPES, pH 7.0, 6 mM MgC12, 20 mM sodium orthovanadate, and 
10 ,UYi per reaction of [Y-~‘P]ATP (3000 Cilmmol, New England Nu- 
clear) to perform the kinase assay. The reactions were allowed to 
proceed for 10 min at 23°C. The samples were subjected to 816% 
SDS-PAGE, and radioactive bands were detected by autoradiogra- 
phy. 
To study the effects of staurosporin on the protein AlsrcNP fusion 
protein kmase activity. the IgG-Sepharose 6FF precipitated periplas- 
mic protein was incubated with mcreasmg concentrations of stauro- 
sporin (0. 1. and 5 pug/ml) for 10 mm at 23°C prior to Initiation of the 
kinase assay as described above. The amount of the protein which 
bound to the IgG-Sepharose after the drug treatment was evaluated 
by immunoblot assay as described below. 
To examine phosphorylation of an exogenous substrate, 10 ,uI of 6 
mg/ml poly(Glu:Tyr) (Sigma) was added before addition of kinase 
buffer, after which the kinase assay was performed as described above. 
2.4. Purlficutlon of protein Altruncated c-src fusion proteins 
Bacterial periplasmic proteins from 2 I of culture were clarified by 
centrifugation at 45,000 xg for 30 mm at 4°C. Clarified bacterial 
periplamic proteins were applied to IgG-Sepharose 6FF column 
(Pharmacia, Piscataway, NJ) and then washed with 10 bed ~01s. of 
washing buffer (10 mM sodium phosphate, pH 7.4, 150 mM NaCl and 
0.1% Triton-X) and 2 bed ~01s. of 5 mM ammonium acetate. pH 5.0. 
The fusion proteins were eluted from the column with 0.5 M ammo- 
nium acetate. The fractions with sigmficant protein concentration 
were pooled, dialized against phosphate buffered saline (PBS), and 
concentrated by using Centricon- concentrators (Amicon, 
Beverly, MA) Protein concentration was determined according to 
Bradford [24]. The purified proteins were resolved on an acrylamide 
gel by SDS-PAGE. In vitro autophosphorylation activity of the puri- 
fied protein was examined by the method described above. 
2.5. Imnunoblot ana!vsrs 
The protein A fusion proteins produced in bacterial cells were de- 
tected by immunoblot analysis. The IgG-Sepharose 6FF precipitated 
periplasmic protein were resolved on an 8816% gradient acrylamide 
gel by SDS-PAGE and transferred to a nitrocellulose membrane 
(Schleicher & Schuell, Keene, NH) for 2 h at 100 V at 4°C. The 
membrane was incubated with PBS containing 5% non-fat dry-milk 
and 0.05% Tween 20 for 30 min. Since protem A could be detected by 
rabbit IgG. the membrane was incubated with horseradish peroxidase 
conjugated rabbit immunoglobulin (Amersham Corp., Arlington 
Heights, IL) for 1 h at room temperature. After rinsing for 30 min with 
PBS contammg 0.3% Tween 20, the membrane was treated with the 
enhanced chemiluminescence (ECL) reagent (Amersham Corp., Ar- 
lington Heights, IL) and then exposed to Amersham Hyperfilm for 5 
min. 
3. RESULTS 
3.1. Bacterial expression of protein Ale-srcNP fusion 
protein 
The bacterial expression vector was constructed using 
the protein A fusion vector pRIT5 (Fig. 1). The trun- 
cated c-src cDNA fragment, designated as c-srcNP, was 
prepared by PCR using pRSVc-srcNP plasmid as a 
PCR template and ligated into the multi-cloning site of 
the vector. c-srcNP contains a deletion of amino acids 
225 
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GNS src-NP SalI. HmcII 
GGC AAT TCC _ GGATCCGTCGACCTGCAG 
Protein A promoter 
Fig. 1 Construction of the protein A/truncated C-SK fusion protem expressIon plasmld The truncated c-.w‘ fragment, designated c-srcNP, was 
amplified by PCR using a pair of primers, SR-I and SR-2, and pRSVc-srcNP plasmid as a PCR template. The purified PCR-amphfied DNA was 
dlgested with EcoRI and BumHI and hgated mto pRIT5 plasmld. The truncated c-src’ gene has linked at the 3’ end of the protein A gene in the 
same reading frame. 
15 to 225 in the c-xc molecule and reportedly has been 
the smallest form of truncated c-src protein that has 
tyrosine kinase activity in the eukaryotic expression sys- 
tem [20]. The E. coli strain DH5cr was then transformed 
by this expression vector containing the c-srcNP frag- 
ment. Since the inserted c-srcNP fragment was prepared 
by the PCR method. which is potentially capable of 
incorporating a wrong base during the amplification. 
the DNA sequence of the insert was confirmed. The 
plasmid clone containing the authentic c-srcNP cDNA 
insert, designated pRITS/srcNP. was used for further 
experiments. 
The protein AlsrcNP fusion protein was precipitated 
with IgG-Sepharose 6FF from the periplasmic proteins 
of pRITS/srcNP transformed bacterical cells and sub- 
jected to a kinase assay as described in section 2. As 
shown in Fig. 2. several phosphorylated proteins were 
detected in the pRIT5lsrcNP transformed bacterial 
cells, whereas no phosphoprotein was detected in the 
pRIT5 transformed bacterial cells. A prominent band 
226 
was observed at the predicted molecular weight of the 
fusion protein (68 kDa), as well as at the site of four 
phosphoproteins of lower molecular weights (65, 50,47, 
25 kDa) when the transformed bacterial cells were cul- 
tured at 37°C. However, in the low-temperature culture 
condition (25°C). the 68-kDa protein was predomi- 
nantly expressed, and the intensities of the lower-molec- 
ular-weight bands were reduced. Additionally, North- 
ern blot analysis revealed that the transformed bacterial 
cells cultured in 37°C had only one transcript detected 
by c-src cDNA probe (data not shown). These results 
indicated that the four lower-molecular-weight proteins 
are most likely proteolytic products of the primary 
translated 6%kDa protein. Further analyses were per- 
formed using the recombinant fusion protein from the 
cells cultured at 25°C. 
In addition to autophosphorylation, the protein A/ 
srcNP fusion protein phosphorylated exogenously 
added poly Glu:Tyr in vitro (Fig. 3). This result con- 
firms the tyrosine kinase activity of the fusion protein. 
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Fig. 2. Autophosphorylation of the bacterially expressed protein A/ 
truncated c-src fusion protein. The fusion protein was precipitated by 
IgG-Sepharose and applied to the in vitro kinase assay as described 
in section 2. Bacteria were grown at 25°C (lane 1) or 37°C (lane 2). 
The soluble protein AlsrcNP fusion proteins were 
purified by using IgG affinity chromatography. As 
shown in Fig. 4, the 6%kDa full-length fusion protein 
was purified with the 47-kDa and the 2%kDa proteins. 
We confirmed that these two co-purified proteins are 
proteolytic products of the full-length fusion protein by 
peptide mapping procedure using cyanogen bromide 
(data not shown). Approximately 100-500 ,ug of the 
6%kDa full-length fusion protein was obtained from a 
2 liters bacterial culture. Moreover, the affinity purified 
soluble protein reserved an autophosphorylation activ- 
ity (Fig. 4, lane 3). 
Suppression of the kinase activity by missense point 
mutation in the ATP-binding domain of the truncated 
c-src. 
In the course of subcloning the srcNP cDNA into the 
pRIT5 plasmid, we obtained a plasmid that had a PCR- 
induced point mutation in the srcNP cDNA. This plas- 
mid was designated pRIT5lsrcNPmu. DNA sequence 
analysis revealed that the pRIT5lsrcNPmu had a mis- 
sense mutation, resulting in a change of Ile (ATA) to 
Thr (ACA) at codon 294 (terminology refers to that the 
full-length c-src cDNA described by Takeya and Hana- 
fusa [25]) (Fig. 5C). Codon 294 is located in the ATP- 
binding domain of the c-src [26]. Previous experiments 
revealed that mutations of full-length pp60’-“” at codon 
295 (Lys + Glu, Lys + His, or Lys + Arg) which is 
closed to this site resulted in a protein without func- 
tional kinase activity [27]. Therefore, the expression and 
activity of this protein derived from pRITS/srcNPmu 
transformed DHSol bacterical cells was determined. Im- 
munoblot analysis revealed that this mutant fusion pro- 
tein was expressed in the periplasmic space at the same 
level as the wild-type clone (Fig. 5A). However, the 
mutant fusion protein had very low in vitro auto- 
phosphorylation activity compared with that of the nor- 
mal fusion protein (Fig. 5B). These results demon- 
strated that Ile-294 as well as Lys-295 is important for 
regulating the kinase activity of pp60”+“. The results 
also revealed that the tyrosine kinase activity is attribut- 
able to the srcNP fusion protein but not to contami- 
nated bacterial kinases. 
3.2. Effects of staurosporin on kinase activity of the f&- 
sion protein 
To determine whether staurosporin, a well-known ki- 
nase inhibitor, could directly affect autophosphoryla- 
tion of the truncated form of the c-src protein, the IgG- 
Sepharose-precipitated fusion protein was preincubated 
with increasing concentrations of the drug and proc- 
essed for kinase assay. As shown in Fig. 6, staurosporin 
reduced autophosphorylation of the fusion protein ki- 
nase. Immunoblot analysis of the staurosporin treated 
fusion protein revealed that the fusion protein was not 
degraded by the drug treatment. These data suggest that 
staurosporin exerts its inhibitory effect on the carboxyl- 
terminal half of the c-src protein. 
4. DISCUSSION 
In the present study, we demonstrate that the bacteri- 
ally expressed carboxy-terminal half of the c-src protein 
fused to the protein A moiety has tyrosine kinase activ- 
ity in vitro. This recombinant truncated c-src protein is 
secreted in the periplasmic space of bacteria and can be 
purified in a simple one-step procedure using IgG-bind- 
ing matrix. The protein demonstrates high efficiency in 
autophosphorylation and substrate phosphorylation. 






Fig. 3. Autophosphorylation and exogeneous substrate phosphoryla- 
tion of the protein A/truncated c-src fusion protein The protein A 
expressed in pRIT5 plasmid transformed DH5a bacterial cells (lanes 
1 and 2), and the protem A/truncated C-SE fusion protein expressed 
m pRITS/srcNP plasmid transformed DHSa bacterial cells (lanes 3 
and 4) were precipitated by IgG-Sepharose and applied to in vitro 
kinase assay without (lane 1 and 3) and with poly(Glu:Tyr) substrate 
(lane 2 and 4). Remarkable autophosphorylation (lane 3) and sub- 
strate phosphorylation (lane 4) by the fusion protein were observed. 
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Fig. 4. Purification of the protein A/truncated C-SIC fusion protein 
using IgG-Sepharose affinity chromatography. Total cell extracts 
(lane 2) and the eluent from IgG-Sepharose column (lane 1) were 
analyzed by SDS-PAGE (8-16% gradient acrylamide gel) and 
Coomassie blue staining. The position of the full-length fusion protein 
(68 kDa) is Indicated by an arrow. The purified fusion protems were 
applied to the in vitro autophosphorylation assay and analyzed by 
SDS-PAGE and autoradiography (lane 3). The 68 kDa protem was 
predominantly phosphorylated. The amount of sample applied on 
each lane corresponded to 10 ml (Jane 1). 100~1 (lane 3) and 1 ml (lane 
3) of origmal bacterial culture. 
teria present significant technical and biologic prob- 
lems. Especially difficult has been the bacterial expres- 
sion of PTK in an enzymatically active form. To date 
only several viral and proto-oncogene PTKs, including 
v-src [lo], v-&l [ll]. v-fps [13], and c-abZ[14]. have been 
expressed in bacterial cells and purified in active form. 
Therefore, mammalian or insect cell expression systems, 
which are more laborious and expensive than bacterial 
expression systems, have been generally applied for pro- 
duction of enzymatically active PTK proteins, and these 
have also not always met with great success. 
A variety of problems may be responsible for the 
difficulties in producing active PTKs in bacterial cells. 
Since there is no direct evidence supporting the possibil- 
ity that bacterial cells contain endogenous PTKs, the 
exogenous recombinant PTKs may seriously affect the 
function of bacterial cellular proteins. In fact, although 
we attempted to transform 5 different E. coli strains 
(DHScr, HBlOl, SURE, MC1061 and NM522) with the 
pRITS/.srcNP plasmid, only DH5a could grow with the 
expression of active truncated c-src whereas the other 
4 strains did not make any transformed colonies (data 
not shown). 
In addition to the toxicity. bacterially expressed 
PTKs are frequently aggregated in insoluble precipi- 
tates and an enzymatically inactive form during the high 
salt and detergent extraction of E. coli [9,28]. We at- 
tempted to express the c-srcNP protein using the gluta- 
thione-S-transferase fusion protein expression system 
[29]. The expressed fusion protein, however, generated 
inclusion bodies, and the small amount of the soluble 
form of the protein did not have PTK activity (data not 
shown). The expression system used in the present study 
allows secretion of the fusion protein in the periplasmic 
space of E. coli [19]. Since the loss of cloned protein by 
aggregation into inclusion bodies can be prevented. the 
protein released slowly into the periplasmic space may 
constitute a biologically active form of the enzyme. Fur- 
thermore, the fusion of the c-src gene to the protein A 
moiety makes it possible to purify the protein by IgG- 
sepharose in a one-step procedure. 
Nemeth et al. previously tested the function of the 
c-srcNP protein using chicken embryo fibroblasts in- 
fected by retroviral expression plasmid pRSVc-srcNP. 
The amino-terminal half-deletion of amino acids 15 to 
225 restricted the ability of c-src to phosphorylate cellu- 
lar substrates in vivo. Since c-srcNP does not contain 
SH2 and SH3 domains, it may not be able to interact 
with critical intracellular molecules and may thus result 
in low levels of in vivo tyrosine phosphorylation and 
non-transformed phenotype of the transfected cells. 
However, the c-srcNP protein displayed an increased in 
vitro PTK activity compared with the full-length c-src 
protein, suggesting that the amino-terminal half may 
A 
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srcNP Arg Val Ala Ile Lys Thr Leu Lys 
-AGA GTG GCC u AAG ACT CTG AAG- 
1 
src NPmu -ADA GTG GCC w AAG ACT CTG AAG- 
Thr 
Fig. 5. Reduction of autophosphorylation activity of the protem A/ 
truncated C-SW fusion protein as a result of a missense mutation at the 
ATP-bindmg domain of the C-SW gene. (A) Protem expression levels 
for pRIT5lsrcNP transformed bacteria (lane 1) and pRIT5lsrcNPmu 
transformed bacteria (lane 2) detected by immunoblot assay. (B) Au- 
tophosphorylation of the fusion protems expressed in pRIT5lsrcNP 
transformed bacteria (lane 1) and pRITS/srcNPmu transformed bac- 
teria (lane 2). (C) Comparison of DNA sequences of the ATP-bmding 
domain of c-src cDNA between pRIT5lsrcNP plasmid and pRITS/ 
srcNPmu plasmid 
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Fig 6. Suppression of autophosphorylation activity of the protein A/truncated c-SYC fusion protein by staurosporin treatment. The fusion protein 
precipited with IgG-sepharose was treated with staurosporin 0 &ml (control; lane l), 1 pg/ml (lane 2). and 5 &ml prior to in vitro kinase assay 
(A) and tmmunoblot assay (B). Staurosporin reduced autophosphorylation of the fusion protein kinase, whereas the amount of the protein which 
bound to the IgG-Sepharose did not change by the drug treatment. 
negatively effect the catalytic activity of the c-src protein 
[20]. Therefore, the carboxyl-terminal half of the c-m 
protein is useful for analyzing the catalytic action of the 
PTK in vitro as well as for understanding the effects of 
SH2 and SH3 domains on phosphorylation of sub- 
strates in vivo. 
Since the fusion protein can be precipitated by IgG- 
sepharose, different mutated forms of c-src protein are 
easily analyzed. As we have shown in this study, one 
amino acid substitution (Ile to Thr) in the ATP-binding 
domain, which was caused by PCR misincorporation, 
significantly reduced the kinase activity of the c-srcNP. 
Further analyses of the effects of other mutations on 
PTK function are in progress. 
Several strategies are being employed in an attempt 
to lower levels of cellular oncogene products vital for 
transformation and thus inhibit malignant transforma- 
tion in oncogene-activated cells. Drugs that inhibit the 
activity of oncogene-encoded PTKs may therefore pro- 
vide a new strategy for cancer treatment. A major prob- 
lem in this area of research has been the lack of a 
high-yield source of pure PTKs, especially cellular 
PTKs such as c-src. Moreover, to screen large numbers 
of putative oncogene-inhibiting compounds, it is neces- 
sary to create new methodologies that are fast, sensitive, 
quantitative, and cost effective. The protein A/c-srcNP 
fusion protein is very useful for the evaluation of com- 
pounds that interact with the catalytic domain of c-src 
kinase as well as for crystallizing the catalytic domain 
of the enzyme. Our studies demonstrated that one 
known inhibitor, staurosporin, was effective in inhibit- 
ing the PTK activity of the fusion protein. 
In summary, the strategy of expressing truncated c- 
src kinase fused to protein A is useful for structural 
analysis of the catalytic domain and diverse enzymol- 
ogical studies to elucidate the interactions of the cata- 
lytic domain with other molecules. 
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